Previous 10 | Next 10 |
home / stock / ibrx / ibrx articles
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday...
Shares of Koninklijke Philips N.V. (NYSE:PHG) rose sharply in today's pre-market trading after reporting first-quarter results. The company al...
ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Friday after the company announced overall survival results in its QUILT 3.055 study. The...
Monday, the FDA approved ImmunityBio Inc’s (NASDAQ:IBRX) Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus ...
Shares of Hibbett, Inc. (NASDAQ:HIBB) rose sharply in today's pre-market trading after the company agreed to be acquired by JD Sports Fashion ...
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Sportradar Group AG (NASDAQ: SRAD) rose sharply durin...
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. ...
Shares of Intuitive Machines, Inc. (NASDAQ: LUNR) fell sharply in today’s pre-market trading. Intuitive Machines revealed Friday that its l...
U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday. Shares of Li Auto Inc. (NASDAQ: LI) ro...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 10:10:00 ET July 9, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Tech, Biotech, Cleantech and Mining Sectors. The newest tech company is involved in AI and Blo...
2024-07-07 01:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer ANKTIVA launch initiates the next era of immunotherapy beyond checkpoint inhibitors that is based on...